IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v14y2023i1d10.1038_s41467-023-39292-w.html
   My bibliography  Save this article

Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration

Author

Listed:
  • Dean Follmann

    (National Institutes of Health)

  • Meagan P. O’Brien

    (Regeneron Pharmaceuticals, Inc.)

  • Jonathan Fintzi

    (National Institutes of Health)

  • Michael P. Fay

    (National Institutes of Health)

  • David Montefiori

    (Duke University Medical Center)

  • Allyson Mateja

    (Frederick National Laboratory for Cancer Research)

  • Gary A. Herman

    (Regeneron Pharmaceuticals, Inc.)

  • Andrea T. Hooper

    (Regeneron Pharmaceuticals, Inc.)

  • Kenneth C. Turner

    (Regeneron Pharmaceuticals, Inc.)

  • Kuo- Chen Chan

    (Regeneron Pharmaceuticals, Inc.)

  • Eduardo Forleo-Neto

    (Regeneron Pharmaceuticals, Inc.)

  • Flonza Isa

    (Regeneron Pharmaceuticals, Inc.)

  • Lindsey R. Baden

    (Brigham and Women’s Hospital)

  • Hana M. El Sahly

    (Baylor College of Medicine)

  • Holly Janes

    (Fred Hutchinson Cancer Research Center)

  • Nicole Doria-Rose

    (National Institutes of Health)

  • Jacqueline Miller

    (Moderna, Inc.)

  • Honghong Zhou

    (Moderna, Inc.)

  • Weiping Dang

    (Moderna, Inc.)

  • David Benkeser

    (Emory University)

  • Youyi Fong

    (Fred Hutchinson Cancer Research Center
    Fred Hutchinson Cancer Research Center
    University of Washington)

  • Peter B. Gilbert

    (Fred Hutchinson Cancer Research Center
    Fred Hutchinson Cancer Research Center
    University of Washington)

  • Mary Marovich

    (National Institutes of Health
    National Institute of Allergy and Infectious Diseases)

  • Myron S. Cohen

    (The University of North Carolina at Chapel Hill)

Abstract

While new vaccines for SARS-CoV-2 are authorized based on neutralizing antibody (nAb) titer against emerging variants of concern, an analogous pathway does not exist for preventative monoclonal antibodies. In this work, nAb titers were assessed as correlates of protection against COVID-19 in the casirivimab + imdevimab monoclonal antibody (mAb) prevention trial (ClinicalTrials.gov #NCT4452318) and in the mRNA-1273 vaccine trial (ClinicalTrials.gov #NCT04470427). In the mAb trial, protective efficacy of 92% (95% confidence interval (CI): 84%, 98%) is associated with a nAb titer of 1000 IU50/ml, with lower efficacy at lower nAb titers. In the vaccine trial, protective efficacies of 93% [95% CI: 91%, 95%] and 97% (95% CI: 95%, 98%) are associated with nAb titers of 100 and 1000 IU50/ml, respectively. These data quantitate a nAb titer correlate of protection for mAbs benchmarked alongside vaccine induced nAb titers and support nAb titer as a surrogate endpoint for authorizing new mAbs.

Suggested Citation

  • Dean Follmann & Meagan P. O’Brien & Jonathan Fintzi & Michael P. Fay & David Montefiori & Allyson Mateja & Gary A. Herman & Andrea T. Hooper & Kenneth C. Turner & Kuo- Chen Chan & Eduardo Forleo-Neto , 2023. "Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration," Nature Communications, Nature, vol. 14(1), pages 1-9, December.
    • Handle: RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-39292-w
    DOI: 10.1038/s41467-023-39292-w
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-023-39292-w
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-023-39292-w?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Eva Stadler & Martin T. Burgess & Timothy E. Schlub & Shanchita R. Khan & Khai Li Chai & Zoe K. McQuilten & Erica M. Wood & Mark N. Polizzotto & Stephen J. Kent & Deborah Cromer & Miles P. Davenport &, 2023. "Monoclonal antibody levels and protection from COVID-19," Nature Communications, Nature, vol. 14(1), pages 1-9, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-39292-w. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.